


## About Ascelia Pharma

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. Our strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. We currently have two drug candidates – Mangoral® and Oncoral – in clinical development.



### MANGORAL® – orphan contrast agent with no competition


Mangoral is a non-gadolinium oral liver contrast agent used for MRI-scans to improve visualisation of focal liver lesions (incl. liver metastases). Detecting liver metastases early is crucial for determining the right treatment method and thus the patient's chances of survival. Mangoral targets patients with severely impaired kidney function who, due to the risk of serious, and potentially fatal, side effects cannot use the currently available contrast agents containing the heavy-metal gadolinium.

Mangoral has completed six Phase I and Phase II studies with strong clinical results and is now entering Phase III. The pivotal Phase III study is a global multicentre study in up to 200 patients. Patient recruitment will start in H2-2019 and final results from the study are expected at the end of 2020 or early 2021.


The addressable market for Mangoral is estimated at USD 350–500 million annually and Mangoral is expected to be the only product on the market for its patient segment. Mangoral has received Orphan Drug Designation from the US Food and Drug Administration (FDA).

#### Patient in Phase II study

**MRI without contrast agent (standard of care) – no metastases found**



**MRI with Mangoral Liver metastases clearly visible**



### ONCORAL – novel oral chemotherapy tablet

Oncoral is our novel oral chemotherapy tablet for the treatment of gastric cancer, which is also considered an orphan drug indication. Oncoral is taken in tablet form, giving patients the opportunity to receive part of their chemotherapy at home and at the same time enabling cost savings for the hospitals.

Oncoral completed Phase I studies with promising results and is now ready for Phase II development. The clinical development strategy for Oncoral is to obtain Phase II data and then enter into collaborations with a suitable partner for further development, market approval and commercialisation.

### Key upcoming news flow and value drivers

	H2-2019	2020	2021	2022
<b>Mangoral®</b>	Phase III, First Patient First Visit	Phase III, Last Patient Last Visit in H2-2020	Phase III Final results	NDA/MAA Application FDA approval Planned sales launch
<b>Oncoral</b>	Phase II Preparation	Phase II Preparation Start, in H2-2020		Phase II completion

### COMPANY FACTS

Founded	2000
Headquarter	Malmö, Sweden
Stock Exchange	NASDAQ Stockholm
Stock ticker	ACE
Drug candidates	Mangoral® and Oncoral
Key Executives	Peter Benson, Chairman Magnus Corfitzen, CEO Carl Bjartmar, CMO Kristian Borbos, CFO

### MARKET DATA (Oct 2019)

Market Cap	SEK 450m
Shares Outstanding	23.5m
Top Shareholders	Sunstone Capital 19.1% CMC-SPV 12.5% Øresund Healthcare 8.6% Alto Invest 5.0% Handelsbanken Funds 4.8% Fjärde AP-fonden 3.9%

### KEY FINANCIALS

SEK million	FY 17/18	FY 18/19
EBIT	-24.7	-37.4
Net profit	-24.4	-37.1
Cash & Liquid assets	55.1	225.0
Equity	111.7	276.1
Operating Cash Flow	-21.0	-30.3

### CALENDAR

Nov 4, 2019	Sw. Shareholders Association, Gothenburg
Nov 8, 2019	Interim Report 3 months 2019/2020
Nov 14, 2019	Annual General Meeting, Malmö
Nov 19, 2019	Redeye Life Science Day, Stockholm
Nov 20-21, 2019	Jefferies Global Healthcare Conf, London
Nov 27, 2019	Vator Unicorn Summit, Stockholm
Dec 1-6, 2019	RSNA, Chicago
Dec 4, 2019	Västra Hamnen fondk. Conf, Malmö

### CONTACTS

<b>Mikael Widell</b> Head of IR mw@ascelia.com M: +46 709 298 269	<b>Kristian Borbos</b> CFO kb@ascelia.com M: +46 735 179 113
--	---

**Ascelia Pharma AB (publ)**  
Per Albin Hanssons väg 41, 205 12 Malmö, Sweden  
ascelia.com